by Peter | Dec 14, 2021 | Research, VISION
By Benjamin Segal, MD, as told to Kara Mayer Robinson We’ve come a long way in treating MS — it’s been one of the biggest success stories in medicine. Over the last 20 years, there has been a revolution in drugs that change the course of the disease,...
by Peter | Dec 14, 2021 | VISION
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical (Mouse Models) Based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity (“NCE”) that affects protein...
by Peter | Nov 14, 2021 | MS Medications, VISION
Overview Establishing and following a treatment plan with your healthcare provider is the best strategy for managing your MS. Medications are used in multiple sclerosis (MS) to modify the disease course, treat relapses — also called attacks...
by Peter | Nov 14, 2021 | Research, VISION
Solutions for People with MS November 9, 2021MS healthcare providers and researchers participated in the 35th Annual Meeting of the Consortium of MS Centers (CMSC) in Orlando, Florida, to share findings and learn the latest about diagnosing and treating MS, and to...
by Peter | Nov 10, 2021 | Research, VIABILITY, VISION
MNT’s Sunday Supplement: Genetic evidence links vitamin D deficiency to mortality risk in someVitamin D is a topic Medical News Today keeps coming back to. We have covered research into the link between vitamin D and the microbiome, the mixed evidence for the health...
by Peter | Nov 2, 2021 | Research, VISION
Spinal cord lesions are more commonly seen in progressive forms of multiple sclerosis, and they can result in an increased risk of disability. Nearly everyone with multiple sclerosis (MS) has signs of lesions in the brain, as shown by magnetic resonance imaging...